CPRX - Catalyst Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Catalyst Pharmaceuticals, Inc.

355 Alhambra Circle
Suite 801
Coral Gables, FL 33134
United States
305 420 3200

Full Time Employees82

Key Executives

NameTitlePayExercisedYear Born
Mr. Patrick J. McEnanyCo-Founder, Chairman, Pres & CEO1.2MN/A1947
Ms. Alicia Grande C.M.A., CPA, CMA, CPAChief Accounting Officer, VP, Treasurer & CFO667.91kN/A1971
Dr. Steven R. Miller Ph.D.COO & Chief Scientific Officer809.03kN/A1962
Dr. Gary Ingenito M.D., Ph.D.Chief Medical & Regulatory Officer751.85kN/A1956
Mr. Jeffrey Del CarmenChief Commercial Officer711.7kN/A1971
Ms. Mary ColemanVP & Head of Investor RelationsN/AN/AN/A
Mr. Brian Elsbernd J.D.Chief Compliance Officer & Chief Legal OfficerN/AN/A1964
Mr. Pete Curry Sr.VP of SalesN/AN/AN/A
Dr. Stanley Iyadurai M.D., Ph.D.Sr. VP of Medical Affairs & Drug DiscoveryN/AN/AN/A
Dr. Preethi Sundaram Ph.D.Chief Strategy OfficerN/AN/A1976
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Corporate Governance

Catalyst Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 30, 2023 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.